Zaleplon controlled release - SkyePharma/Somnus

Drug Profile

Zaleplon controlled release - SkyePharma/Somnus

Alternative Names: SKP-1041

Latest Information Update: 09 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SkyePharma AG
  • Developer Somnus Therapeutics
  • Class Acetamides; Hypnosedatives; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Sleep maintenance insomnia

Most Recent Events

  • 23 Apr 2012 Zaleplon controlled release - SkyePharma/Somnus is available for licensing as of 23 Apr 2012. www.somnusthera.com
  • 16 Jun 2011 Final efficacy data from a phase II trial in Sleep maintenance insomnia released by Somnus Therapeutics
  • 28 Feb 2011 Somnus Therapeutics completes a phase II trial in Sleep maintenance insomnia in USA (NCT00878553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top